Delving into the Latest Updates on HAL Allergy BV with Synapse

概览

疾病领域	数量

免疫系统疾病	1
感染	1

排名前五的药物类型	数量

变应原提取物	1

关联

3

项与 HAL Allergy BV 相关的药物

House dust mite allergy immunotherapy sublingual

靶点-

作用机制

免疫调节剂

在研机构

HAL Allergy Holding BV [+1]

原研机构

HAL Allergy Holding BV

在研适应症

过敏性鼻结膜炎 [+2]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

德国

首次获批日期2013-09-13

Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)

靶点-

作用机制

免疫调节剂

在研机构

HAL Allergy Holding BV

原研机构

HAL Allergy Holding BV

在研适应症

变应性结膜炎

非在研适应症

过敏性鼻结膜炎 [+3]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期-

HAL-MRE1

靶点-

作用机制

免疫调节剂

在研机构-

原研机构

HAL Allergy BV

在研适应症-

非在研适应症

过敏性鼻结膜炎 [+1]

最高研发阶段无进展

首次获批国家/地区-

首次获批日期-

4

项与 HAL Allergy BV 相关的临床试验

NCT03758456 / Completed临床1期

A Randomized, Double-blind, Placebo Controlled Study to Assess the Safety and Tolerability of HAL-MRE1 Subcutaneous Immunotherapy in Adult Subjects With Ragweed Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma

The aim of this first-in-human phase I study is to assess the safety and tolerability of HAL-MRE1 subcutaneous immunotherapy in subjects suffering from ragweed pollen-induced allergic rhinitis/rhinoconjunctivitis with or without asthma.
The study has 4 treatment groups: 1 placebo group and 3 groups treated with different doses of HAL-MRE1.

开始日期2018-11-21

申办/合作机构

HAL Allergy BV

EUCTR2009-015012-18-DE / Not yet recruitingN/A

A prospective, randomized, open, multi-centre study to assess safety of PURETHAL Grasses given with a rush induction schedule to patients with allergic rhinoconjunctivitis. - PURETHAL Grasses Rush study

开始日期2010-02-09

申办/合作机构

HAL Allergy BV

EUCTR2005-005175-16-DE / Not yet recruitingN/A

Twin SUBLIVAC® Grasses Clinical Efficay Study

开始日期2006-07-20

申办/合作机构

HAL Allergy BV

100 项与 HAL Allergy BV 相关的临床结果

登录后查看更多信息

0 项与 HAL Allergy BV 相关的专利（医药）

登录后查看更多信息

6

项与 HAL Allergy BV 相关的文献（医药）

2023-08-01·Journal of Allergy and Clinical Immunology

IgE cross-inhibition between Ara h 1 and Ara h 2 is explained by complex formation of both major peanut allergens

Article

作者: van Ree, Ronald ; Akkerdaas, Jaap H. ; Dreskin, Stephen C. ; Versteeg, Serge A. ; Warmenhoven, Hans J. M. ; Hulsbos, Luuk

Surprisingly, IgE cross-reactivity between the major peanut allergens Ara h 1, 2, and 3 has been reported despite very low sequence identities.We investigated the unexpected cross-reactivity between peanut major allergens.Cross-contamination of purified natural Ara h 1, 2, 3, and 6 was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), Western blot test, liquid chromatog.-tandem mass spectrometry (LC-MS/MS), and sandwich ELISA (ELISA).IgE cross-reactivity was studied with sera of peanut-allergic patients (n = 43) by ELISA and ImmunoCAP inhibition using both intact natural and recombinant allergens and synthetic peptides representing postulated Ara h 1 and Ara h 2 cross-reactive epitopes.Both purified nAra h 1 and nAra h 3 were demonstrated to contain small but significant amounts of Ara h 2 and Ara h 6 (<1%) by sandwich ELISA, SDS-PAGE/Western blot anal., and LC-MS/MS.IgE cross-inhibition between both 2S albumins and Ara h 1 and Ara h 3 was only observed when using natural purified allergens, not recombinant allergens or synthetic peptides.Apparent cross-reactivity was lost when purified nAra h 1 was pretreated under reducing conditions, suggesting that Ara h 2 and Ara h 6 contaminations may be covalently bound to Ara h 1 via disulfide interactions.True cross-reactivity of both peanut 2S albumins with Ara h 1 and Ara h 3 could not be demonstrated.Instead, cross-contamination with small quantities was shown to be sufficient to cause significant cross-inhibition that can be misinterpreted as mol. cross-reactivity.Diagnostic tests using purified nAra h 1 and nAra h 3 can overestimate their importance as major allergens as a result of the presence of contaminating 2S albumins, making recombinant Ara h 1 and Ara h 3 a preferred alternative.

2021-02-01·Int. Journal of Clinical Pharmacology and Therapeutics4区 · 医学

The mode of action of sugammadex on coagulation

4区 · 医学

Article

作者: Kluft, Cornelis ; de Kam, Pieter-Jan ; Burggraaf, Jacobus ; Moerland, Matthijs ; Kruithof, Annelieke C. ; Laterveer, Ria H.

OBJECTIVETo explore the mode of action (MoA) by which sugammadex interferes with coagulation.MATERIALS AND METHODSThe effect of sugammadex on various steps in the coagulation cascade including thrombin generation, factor Xa activity, and factor Xa generation was explored in human plasma.RESULTSSugammadex did not affect a conventional thrombin generation test (TGT), while it prolongs activated partial thromboplastin time (APTT) and prothrombin time (PT). However, a customized TGT with PT reagent revealed sugammadex effects. In addition, sugammadex prolonged a one-step prothrombinase-induced clotting time (PiCT) using human factor Xa. Furthermore, sugammadex interfered with factor Xa generation induced by an intrinsic and not by an extrinsic activator, nor by Russell's viper venom factor X (RVV-X).CONCLUSIONAdapted, rather than standard, experiments show that sugammadex is likely to decrease factor Xa activity in the common pathway and activation of factor X specifically in the intrinsic pathway.

2011-05-19·New England Journal of Medicine1区 · 医学

Anaphylaxis from Passive Transfer of Peanut Allergen in a Blood Product

1区 · 医学

Letter

作者: Elisabeth C.M. van Pampus ; Irma Joosten ; Joseph L. Baumert ; Paul P. Brons ; Stef J. Koppelman ; Joannes F.M. Jacobs

Anaphylactic transfusion reactions from passive transfer of IgE have been documented, but a case is now reported in which the eliciting factor was a food allergen in peanuts ingested by blood donors before donation.

100 项与 HAL Allergy BV 相关的药物交易

登录后查看更多信息

100 项与 HAL Allergy BV 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

批准上市

1

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

House dust mite allergy immunotherapy sublingual	过敏性鼻结膜炎更多	批准上市
HAL-MRE1	过敏性鼻结膜炎更多	无进展
Phleum pratense pollen allergy immunotherapy(HAL Allergy Holding BV)	过敏性鼻炎更多	无进展